Qiagen's Q4 Revenues Increase 17 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen announced after the close of the market Tuesday that its fourth quarter sales grew 17 percent or 11 percent organically.

For the quarter ended Dec. 31, 2011, the molecular diagnostics firm generated sales of $334.4 million, up from $286 million a year ago, surpassing analyst estimates of $323.3 million.

The acquisitions of Cellestis and Ipsogen provided 6 percentage points to growth, the company said, adding that currency had no effect on sales growth.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.